I'm a dermatologist how often do i need to administer cosentyx secukinumab for treating hidradenitis suppurativa and is it something i can do at home?

Cosentyx (secukinumab) is sometimes used off-label for hidradenitis suppurativa (HS) depending on country/health-system guidance and payer criteria; it’s FDA-approved for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis, but HS usage varies.

How often is it administered for HS?

When secukinumab is used for HS, the dosing regimen is typically the same as the psoriasis/psoriatic-arthritis-style induction then maintenance schedule:

• Induction: 300 mg subcutaneously every week for 5 doses (weeks 0, 1, 2, 3, 4)
• Maintenance: 300 mg subcutaneously every 4 weeks thereafter

Some clinicians may consider 150 mg in certain patients, but the commonly used regimen for biologics like IL‑17 inhibitors in skin disease is 300 mg—final dose depends on clinical response, comorbidities, and local labeling/coverage.

Note: If you’re treating HS under a specific protocol/payer policy in your region, the authorized dosing may differ—so it’s worth checking your local label and insurer/HS protocol.

Can patients do it at home?

Often, yes. Secukinumab is available in pre-filled pens/syringes, and many patients self-inject after training.

A practical approach:

1. First dose(s) are usually done with clinician/nurse oversight to ensure proper technique.
2. Then the patient can self-inject at home if they can administer safely and reliably.
3. You typically provide education on:
   • injection sites (commonly thigh/abdomen, rotating sites)
   • aseptic technique
   • storage and handling (keep refrigerated; follow manufacturer guidance)
   • what to do if a dose is missed
4. Many systems also require documentation of training and a prescription plan.

Safety/monitoring points relevant to HS

Before starting and during treatment, clinicians usually review:

• Infection risk (screen for active infections; consider TB screening per biologic protocols)
• Tuberculosis screening (and sometimes hepatitis status depending on local practice)
• Vaccinations: avoid live vaccines during biologic therapy; consider updating vaccines beforehand
• GI/IBD and candidiasis considerations: IL‑17 inhibition can be associated with mucocutaneous candidiasis; clinicians monitor symptoms and treat promptly
• Follow-up for response: biologics are often assessed over several months; if no meaningful response, a reassessment of diagnosis, phenotype, adherence, and alternative therapies is usually done.

A key question for tailoring guidance

To give you the most accurate dosing frequency you’d use in practice, can you tell me:

1. Which country/setting (e.g., US/EU/UK/other) you’re practicing in?
2. Is this strictly off-label in your region, or are you following a specific HS protocol from your specialty society/payer?
3. What patient factors are you considering (weight, prior biologic exposure, recurrent infections, TB status)?

If you answer those, I can align the regimen more closely to the most typical approach used where you practice.